St. Jude Protocol for Average-Risk Medulloblastoma

Introduction to the Protocol

• The National Comprehensive Cancer Network recommends the St. Jude protocol for average-risk medulloblastoma, which consists of weekly vincristine during craniospinal irradiation and maintenance chemotherapy with vincristine, cisplatin, and cyclophosphamide 1, 2, 3

Radiation Therapy Component

• The St. Jude protocol involves craniospinal irradiation with a dose of 23.4 Gy to the craniospinal axis, followed by an involved field boost to a total dose of 54 Gy to the primary tumor site 3, 4
• Concurrent chemotherapy with weekly vincristine is administered during the 6-week radiation period 1, 2, 3, 5

Maintenance Chemotherapy Regimen

• The St. Jude maintenance protocol uses a three-drug combination of vincristine, cisplatin, and cyclophosphamide, which is different from the COG protocol 1, 2, 3

Key Protocol Features

• The St. Jude protocol was validated in a study of 330 patients with average-risk medulloblastoma, with outcomes comparable to other prospective studies 1, 2, 6
• Group 4 tumors comprised the largest molecular subtype proportion in this trial 1, 2

Critical Monitoring Requirements

• The National Comprehensive Cancer Network recommends monitoring patients closely for vincristine-associated peripheral neuropathy and cisplatin-associated ototoxicity 4, 5

Important Protocol Considerations

• The St. Jude and COG protocols are not interchangeable, and mixing protocols may compromise outcomes and complicate toxicity management 2, 3
• Radiation therapy should begin within one month postoperatively, based on general CNS tumor guidelines 7
• Average-risk classification requires meeting specific criteria, including M0 disease, classic histology, and gross total resection or near-total resection 3, 4

Radiation Considerations

• Radiation is not recommended for patients under 3 years of age, though radiation-avoiding strategies may be considered for patients over 3 years at the treating physician's discretion 3, 4

Common Pitfalls to Avoid

• The National Comprehensive Cancer Network recommends against using low-dose CSI (<23.4 Gy) and delaying radiation therapy, as these approaches may compromise outcomes 1, 2, 7
• Switching between protocols mid-treatment is also not recommended, as the COG and St. Jude maintenance regimens differ significantly and are not interchangeable 2, 3

St. Jude Protocol for Average-Risk Medulloblastoma

Protocol Considerations

• The American Society of Clinical Oncology recommends not capping vincristine at 1 mg, as the protocol specifies 1.4 mg/m² with a 2 mg maximum 8